NASDAQ:AXNXAxonics Modulation Technologies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Axonics Modulation Technologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $37.60 +0.72 (+1.95 %) (As of 06/3/2020 08:58 AM ET) Add Compare Share Today's Range$36.21Now: $37.60▼$37.9750-Day Range$27.31MA: $34.79▼$39.8252-Week Range$15.25Now: $37.60▼$43.37Volume384,503 shsAverage Volume735,985 shsMarket Capitalization$1.30 billionP/E RatioN/ADividend YieldN/ABeta0.19 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Axonics Modulation Technologies, Inc., a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention. Its proprietary r-SNM System delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of urinary and fecal dysfunction. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was founded in 2012 and is based in Irvine, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAxonics Modulation Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $42.67, Axonics Modulation Technologies has a potential upside of 13.5% from its current price of $37.60.Amount of Analyst CoverageAxonics Modulation Technologies has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.7 Community Rank Outperform VotesAxonics Modulation Technologies has received 105 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAxonics Modulation Technologies has received 88 “underperform” votes. (Add your “underperform” vote.)Community SentimentAxonics Modulation Technologies has received 54.40% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Axonics Modulation Technologies and other stocks. Vote “Outperform” if you believe AXNX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AXNX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAxonics Modulation Technologies does not currently pay a dividend.Dividend GrowthAxonics Modulation Technologies does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axonics Modulation Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,665,797.00 in company stock.Percentage Held by Insiders35.99% of the stock of Axonics Modulation Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.55% of the stock of Axonics Modulation Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axonics Modulation Technologies are expected to grow in the coming year, from ($1.94) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axonics Modulation Technologies is -13.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axonics Modulation Technologies is -13.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxonics Modulation Technologies has a P/B Ratio of 5.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.77 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXNX Previous Symbol CUSIPN/A CIKN/A Webwww.axonics.com Phone949-396-6322Debt Debt-to-Equity Ratio0.09 Current Ratio10.28 Quick Ratio9.31Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$13.82 million Price / Sales93.92 Cash FlowN/A Price / Cash FlowN/A Book Value$6.40 per share Price / Book5.88Profitability EPS (Most Recent Fiscal Year)($2.80) Net Income$-79,930,000.00 Net Margins-208.60% Return on Equity-57.95% Return on Assets-45.90%Miscellaneous Employees87 Outstanding Shares34,520,000Market Cap$1.30 billion Next Earnings Date8/3/2020 (Estimated) OptionableNot Optionable NASDAQ:AXNX Rates by TradingView Receive AXNX News and Ratings via Email Sign-up to receive the latest news and ratings for AXNX and its competitors with MarketBeat's FREE daily newsletter. Axonics Modulation Technologies (NASDAQ:AXNX) Frequently Asked Questions How has Axonics Modulation Technologies' stock been impacted by COVID-19 (Coronavirus)? Axonics Modulation Technologies' stock was trading at $30.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AXNX shares have increased by 24.4% and is now trading at $37.60. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Axonics Modulation Technologies? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axonics Modulation Technologies in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Axonics Modulation Technologies. When is Axonics Modulation Technologies' next earnings date? Axonics Modulation Technologies is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Axonics Modulation Technologies. How were Axonics Modulation Technologies' earnings last quarter? Axonics Modulation Technologies Inc (NASDAQ:AXNX) released its earnings results on Tuesday, May, 5th. The company reported ($0.43) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.60) by $0.17. The firm had revenue of $26.30 million for the quarter, compared to analysts' expectations of $14.47 million. Axonics Modulation Technologies had a negative return on equity of 57.95% and a negative net margin of 208.60%. The firm's revenue for the quarter was up 2341.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.47) earnings per share. View Axonics Modulation Technologies' earnings history. What price target have analysts set for AXNX? 9 equities research analysts have issued 1 year target prices for Axonics Modulation Technologies' shares. Their forecasts range from $35.00 to $48.00. On average, they anticipate Axonics Modulation Technologies' stock price to reach $42.67 in the next year. This suggests a possible upside of 13.5% from the stock's current price. View analysts' price targets for Axonics Modulation Technologies. Has Axonics Modulation Technologies been receiving favorable news coverage? News articles about AXNX stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Axonics Modulation Technologies earned a news impact score of 2.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutAxonics Modulation Technologies. Who are some of Axonics Modulation Technologies' key competitors? Some companies that are related to Axonics Modulation Technologies include Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), Nevro (NVRO), ICU Medical (ICUI), Irhythm Technologies (IRTC), NuVasive (NUVA), Merit Medical Systems (MMSI), Inovio Pharmaceuticals (INO), Inspire Medical Systems (INSP), AtriCure (ATRC), Cantel Medical (CMD), Glaukos (GKOS), Luminex (LMNX), Shockwave Medical (SWAV) and Cardiovascular Systems (CSII). View all competitors. What other stocks do shareholders of Axonics Modulation Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics Modulation Technologies investors own include Oasis Petroleum (OAS), CVS Health (CVS), Honeywell International (HON), AT&T (T), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Home Depot (HD), Altria Group (MO) and Procter & Gamble (PG). Who are Axonics Modulation Technologies' key executives? Axonics Modulation Technologies' management team includes the following people: Mr. Raymond W. Cohen, CEO & Director (Age 60)Mr. Danny L. Dearen, Pres & CFO (Age 56)Dr. Karen L. Noblett M.D., M.A.S., Chief Medical Officer (Age 56)Mr. Rinda K. Sama, Chief Operating Officer (Age 40)Mr. Guangqiang Jiang Ph.D., Chief Technology Officer (Age 46) When did Axonics Modulation Technologies IPO? (AXNX) raised $100 million in an initial public offering on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers. What is Axonics Modulation Technologies' stock symbol? Axonics Modulation Technologies trades on the NASDAQ under the ticker symbol "AXNX." Who are Axonics Modulation Technologies' major shareholders? Axonics Modulation Technologies' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.41%), Redmile Group LLC (4.37%), AXA (2.68%), Lord Abbett & CO. LLC (2.33%), Cormorant Asset Management LP (2.32%) and Blackcrane Capital LLC (2.17%). Company insiders that own Axonics Modulation Technologies stock include Andera Partners, Bakker Juliet Tammenoms, Cormorant Asset Management, Lp, Danny L Dearen, Geoff Pardo, Healthcare Holding BV Gilde, John Woock, Michael V Williamson, Nancy Lynn Md Snyderman, Raphael Wisniewski, Raymond W Cohen and Rinda Sama. View institutional ownership trends for Axonics Modulation Technologies. Which institutional investors are selling Axonics Modulation Technologies stock? AXNX stock was sold by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Cormorant Asset Management LP, Peregrine Capital Management LLC, Redmile Group LLC, Morgan Stanley, Magnetar Financial LLC, Squarepoint Ops LLC, and UBS Group AG. Company insiders that have sold Axonics Modulation Technologies company stock in the last year include Andera Partners, Danny L Dearen, Geoff Pardo, John Woock, Michael V Williamson, Raphael Wisniewski, Raymond W Cohen, and Rinda Sama. View insider buying and selling activity for Axonics Modulation Technologies. Which institutional investors are buying Axonics Modulation Technologies stock? AXNX stock was purchased by a variety of institutional investors in the last quarter, including AXA, Lord Abbett & CO. LLC, Blackcrane Capital LLC, C WorldWide Group Holding A S, Samlyn Capital LLC, Rhenman & Partners Asset Management AB, BlackRock Inc., and Russell Investments Group Ltd.. Company insiders that have bought Axonics Modulation Technologies stock in the last two years include Bakker Juliet Tammenoms, Cormorant Asset Management, Lp, Healthcare Holding BV Gilde, Nancy Lynn Md Snyderman, and Raymond W Cohen. View insider buying and selling activity for Axonics Modulation Technologies. How do I buy shares of Axonics Modulation Technologies? Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Axonics Modulation Technologies' stock price today? One share of AXNX stock can currently be purchased for approximately $37.60. How big of a company is Axonics Modulation Technologies? Axonics Modulation Technologies has a market capitalization of $1.30 billion and generates $13.82 million in revenue each year. The company earns $-79,930,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis. Axonics Modulation Technologies employs 87 workers across the globe. What is Axonics Modulation Technologies' official website? The official website for Axonics Modulation Technologies is www.axonics.com. How can I contact Axonics Modulation Technologies? Axonics Modulation Technologies' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company can be reached via phone at 949-396-6322. This page was last updated on 6/3/2020 by MarketBeat.com Staff
